SCHEMBL4806050

SCHEMBL4806050

CCCCC[C@@H](CO)CCC

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.85
ALDH1A1 P00352 2/20 0.61
CYP2D6 P10635 2/20 0.45
SPHK1 Q9NYA1 1/20 0.45
GMNN O75496 1/20 0.45
POLB P06746 1/20 0.45
THPO P40225 1/20 0.45
MTOR P42345 1/20 0.45
BLM P54132 1/20 0.45
KDM4E B2RXH2 1/20 0.45
TP53 P04637 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
MAPT P10636 1/20 0.45
CETP P11597 1/20 0.45
HTT P42858 1/20 0.45
UBE2N P61088 1/20 0.45
TSHR P16473 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
OPRM1 P35372 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17526461 1.00 LMNA (0.85) LMNAALDH1A1CYP2D6SPHK1GMNN
SCHEMBL21366 1.00 LMNA (0.85) LMNAALDH1A1CYP2D6SPHK1GMNN
SCHEMBL8419131 0.97 LMNA (0.90) LMNAALDH1A1CYP2D6SPHK1GMNN
SCHEMBL5878924 0.97 LMNA (0.90) LMNAALDH1A1CYP2D6SPHK1GMNN
SCHEMBL16896978 0.97 LMNA (0.90) LMNAALDH1A1CYP2D6SPHK1GMNN
SCHEMBL25210796 0.97 LMNA (0.90) LMNAALDH1A1CYP2D6SPHK1GMNN
SCHEMBL15936482 0.97 LMNA (0.90) LMNAALDH1A1CYP2D6SPHK1GMNN
SCHEMBL20679043 0.97 LMNA (0.90) LMNAALDH1A1CYP2D6SPHK1GMNN
SCHEMBL20678866 0.97 LMNA (0.90) LMNAALDH1A1CYP2D6SPHK1GMNN
SCHEMBL25254930 0.97 LMNA (0.90) LMNAALDH1A1CYP2D6SPHK1GMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4536751-A1 COMPOSITION BASED ON A POLYMERIZABLE COMPONENT AND A THIXOTROPIC ADDITIVE ARKEMA FRANCE (FR) 2025-04-16 EP disclosed
WO-2023237595-A1 COMPOSITION BASED ON A POLYMERIZABLE COMPONENT AND A THIXOTROPIC ADDITIVE ARKEMA FRANCE (FR) 2023-12-14 WO disclosed
EP-4255955-A1 THIXOTROPIC DIUREA-DIURETHANE COMPOSITION ARKEMA FRANCE (FR) 2023-10-11 EP disclosed
WO-2022122617-A1 THIXOTROPIC DIUREA-DIURETHANE COMPOSITION ARKEMA FRANCE (FR) 2022-06-16 WO disclosed
WO-2020046670-A1 CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USE IN ACID STIMULATION OPERATIONS KAO CORPORATION (JP) 2020-03-05 WO disclosed
US-20160039879-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF S&T GLOBAL INC. (US) 2016-02-11 US disclosed
US-7335235-B2 Alkoxylate mixtures and detergents containing the same BASF AKIENGESELLSCHAFT (DE) 2008-02-26 US disclosed
US-20050170991-A1 Alkoxylate mixtures and detergents containing the same BASF AKTIENGESELLSCHAFT (DE) 2005-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160039879-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF FKBP1B, MALT1, FKBP5 LMNA 3497/4885ALDH1A1 2376/4885CYP2D6 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.